Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

48 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling by array of human HL-60 cells treated with anacardic acid

ABSTRACT: The aim of the experiment was to identify the genes up or downregulated by hyposumoylation induced by anacardic acid, an inhibitor of SUMO activating enzyme, in Acute Myeloid Leukemia cell line HL-60

ORGANISM(S): Homo sapiens

SUBMITTER: TONY KAOMA

PROVIDER: E-MTAB-2382 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.

Bossis Guillaume G Sarry Jean-Emmanuel JE Kifagi Chamseddine C Ristic Marko M Saland Estelle E Vergez François F Salem Tamara T Boutzen Héléna H Baik Hayeon H Brockly Frédérique F Pelegrin Mireia M Kaoma Tony T Vallar Laurent L Récher Christian C Manenti Stéphane S Piechaczyk Marc M

Cell reports 20140605 6

Chemotherapeutic drugs used in the treatment of acute myeloid leukemias (AMLs) are thought to induce cancer cell death through the generation of DNA double-strand breaks. Here, we report that one of their early effects is the loss of conjugation of the ubiquitin-like protein SUMO from its targets via reactive oxygen species (ROS)-dependent inhibition of the SUMO-conjugating enzymes. Desumoylation regulates the expression of specific genes, such as the proapoptotic gene DDIT3, and helps induce ap ...[more]

PMID: 24910433

Similar Datasets

Genes rapidly regulated by Ara-C and DNR treatment of HL-60 AML cells and role of NADPH-oxidase derived ROS in DNR-induced gene expression

Project description:Daunorubicin (DNR) and Cytarabin (Ara-C) are the main chemotherapeutic drugs used for Acute Myeloid Leukemias (AML) treatment. However, their mode of action is not well understood. To decipher if these drug would induce rapid transcriptional reprogramming, we treated HL-60 AML cell line with DNR or Ara-C for 3 hours and carried out a transcriptomic analyses. In addition, we had shown that Reactive Oxigen Species (ROS) produced by NADPH oxidases (NOX) are involved in DNR-induced gene expression. We therefore also performed a transcriptomic analyses in HL-60 cells treated with DNR and VAS2870, an NADPH oxidase inhibitor. HL-60 cells were treated or not for 3 hours with 2 ÂµM Ara-C, 1 ÂµM DNR or 1 ÂµM DNR + 20ÂµM VAS 2870. RNAs were purified from 3 independent experiments and used to probe Affymetrix Human Gene 2.0 ST Genechips

2017-12-31 | E-MTAB-4895 | biostudies-arrayexpress

Differentiated vs. undifferentiated promyelocytic cell lines (HL-60 and KG-1) and Neutrophiles

Project description:We identify the tetraspanin CD82 as the recognition site for xenogeneic endothelial cells independently of Gala1,3-gal structures. We demonstrate that in contrast to undifferentiated cells, differentiated promyelocytic cell lines (HL-60, THP-1 and KG-1) are capable of recognizing xenogeneic porcine endothelial cells in a calcium-dependent manner. We used serial analysis of gene expression (SAGE) to identify the differentially expressed transcripts in these cell lines. Interrogation of these transcripts revealed a number of differentially expressed genes that include the Gala1,3-gal-independent recognition moiety(s). Comparing these SAGE transcripts with those expressed in resting human naive neutrophils identified the tetraspanin CD82 as the most likely candidate responsible for xenogeneic recognition. Blocking antibodies to CD82 in human naive neutrophils inhibited the calcium response and abolished the subsequent Reactive Oxygen Metabolite (ROM) production evoked by the xenogeneic encounter of either Gala1,3-gal knockout or wild-type porcine aortic endothelial cells. Our data identify CD82 on innate immune cells as the major recognition moiety of the xenogeneic endothelium, independently of Gala1,3-gal-structures and open new avenues of intervention to making xenotransplantation a clinical reality. We used serial analysis of gene expression (SAGE) to identify the differentially expressed transcripts in promyelocytic cell lines (HL-60, THP-1 and KG-1) upon differentiation. We looked for genes common to the differentiation pathway in these cell lines but absent from the control naiive neutrophiles.

2013-08-05 | E-GEOD-43211 | biostudies-arrayexpress

Application of SPOT to Zn-treated HL-60 cells for multi-omics mechanism discovery, phosphoproteomics

Project description:Application of SPOT to Zn-treated HL-60 cells for multi-omics mechanism discovery. A time-resolved, multi-omics experiment using an automated, unified sample preparation platform. These datasets represent additional phosphoproteomics datasets(not prepared using SPOT) that were used along with the SPOT datasets for mechanism discovery

2018-11-21 | PXD009367 | Pride

HL-60 treated with TPA

Project description:Comparing the difference between TPA stimulated HL-60 and control

2013-05-05 | GSE29620 | GEO

Epichromatin HL-60/S4

Project description:Epichromatin HL-60/S4

| PRJEB5782 | ENA

Epichromatin HL-60/S4

Project description:Characterization of epichromatin by immunoprecipitation-DNA sequencing of formaldehyde-fixed and sonicated HL-60/S4 cells.

2015-12-31 | E-MTAB-2360 | biostudies-arrayexpress

SUMO-2/3 ChIP-Seq in HL-60 cells treated or not with Daunorubicin, Cytarabin and the Nox inhibitor VAS2870

Project description:Acute Myeloid Leukemia cell line HL-60 were treated with 1 M daunorubicin (DNR) or 2M cytarabin (Ara-C) or 1 M DNR + 10 M VAS2870 (NADPH oxidase inhibitor) for 2 hours. ChIP-Seq experiments were carried out with SUMO-2/3 antibodies. Immunoprecipitated DNA and corresponding inputs from 3 independent experiments were pooled and processed for deep-sequencing (Hi-SEq 2000, Illumina).

2023-12-30 | E-MTAB-4947 | biostudies-arrayexpress

SUMO2/3 CHIP-Seq in HL-60 cells treated or not with cytarabine or daunorubicine

Project description:SUMOylation, a post-translational modification of the ubiquitin family plays key roles in Acute Myeloid Leukemias response to therapies, in particular through the regulation of gene expression. We have investigated here how daunorubicine (DNR) and cytarabine (Ara-C), the two main drugs used for Acute Myeloid Leukemia treatment, affect the distribution of SUMO on chromatin in the HL-60 cell lines. We found that DNR but not Ara-C leads to a massive decrease in the presence of SUMOylated proteins on the chromatin, in particular at promoters and enhancers, where they are enriched.

2023-06-23 | GSE198985 | GEO

Application of SPOT to Zn-treated HL-60 cells for multi-omics mechanism discovery

Project description:Application of SPOT to Zn-treated HL-60 cells for multi-omics mechanism discovery. A time-resolved, multi-omics experiment using an aumtomated, unified sample preparation platform

2018-11-21 | PXD009149 | Pride

microRNA-seq from HL-60 (ENCSR645VXJ)

Project description:RNA Evaluation HL-60 derived M0 macrophages microRNA-seq from Mortazavi For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2022-12-04 | GSE219578 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data